Understanding asthma flare-ups in patients treated with mepolizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the nature of asthma exacerbations in patients receiving mepolizumab over a two-year period. Participants will undergo assessments every six months, as well as during any asthma exacerbations, to evaluate clinical, physiological, and inflammatory outcomes. The study will record patient demographics and various health measures before treatment and at specified intervals throughout the study. The focus will be on determining the type of inflammatory exacerbation based on sputum eosinophils and neutrophils.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
* Eligible for mepolizumab treatment
* Able and willing to sign the informed consent form

Exclusion Criteria:

* Any respiratory disease apart from asthma
* Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome

Where it's running

• Institut universitaire de cardiologie et de pneumologie de Québec
  Québec, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Andréanne Côté, MD — Iucpq-Ul
• Study coordinator: Marie-Eve Boulay, MSc
• Email: marie-eve.boulay@criucpq.ulaval.ca
• Phone: 4186568711

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying biomarkers for response to mepolizumab in patients with nasal polyps and asthma

  This study is testing if mepolizumab can help people with nasal polyps and asthma feel better, while also looking for signs that show who will benefit from the treatment.

  Recruiting at 2 sites Aristotle University Of Thessaloniki · Thessaloniki, Exochi and 1 other locations · NCT05708300

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.